Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
Saved in:
| Title: | Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. |
|---|---|
| Authors: | Fay JW; Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, TX 75204, USA. josephf@baylorhealth.edu, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, Ueno H, Banchereau J |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2006 Oct; Vol. 55 (10), pp. 1209-18. Date of Electronic Publication: 2005 Dec 06. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0340-7004 (Print) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
